Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,339
  • Shares Outstanding, K 28,766
  • Annual Sales, $ 670 K
  • Annual Income, $ -23,850 K
  • 60-Month Beta 1.12
  • Price/Sales 143.83
  • Price/Cash Flow N/A
  • Price/Book 1.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.40
  • Number of Estimates 3
  • High Estimate -0.30
  • Low Estimate -0.46
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -53.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.06 +8.50%
on 11/27/19
4.06 -18.23%
on 11/11/19
-0.64 (-16.16%)
since 11/08/19
3-Month
3.06 +8.50%
on 11/27/19
5.86 -43.34%
on 09/12/19
-1.88 (-36.15%)
since 09/10/19
52-Week
2.56 +29.69%
on 03/12/19
16.65 -80.06%
on 04/09/19
-0.35 (-9.54%)
since 12/10/18

Most Recent Stories

More News
PhaseBio to Present at Stifel 2019 Healthcare Conference

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

PHAS : 3.32 (+3.43%)
PHASEBIO PHARMA (PHAS) Reports Q3 Loss, Misses Revenue Estimates

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -11.11% and -31.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PHAS : 3.32 (+3.43%)
PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

PHAS : 3.32 (+3.43%)
PhaseBio Expands Executive Management Team

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

PHAS : 3.32 (+3.43%)
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced...

PHAS : 3.32 (+3.43%)
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary orphan diseases, today...

PHAS : 3.32 (+3.43%)
Pharmacodynamics Evaluation of PhaseBio's Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that data...

PHAS : 3.32 (+3.43%)
PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that pharmacodynamic...

PHAS : 3.32 (+3.43%)
PhaseBio To Report Second Quarter 2019 Financial Results and Recent Corporate Progress on August 13, 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced it will...

PHAS : 3.32 (+3.43%)
PhaseBio Added to Russell 2000(R) and 3000(R) Indexes

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the...

PHAS : 3.32 (+3.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PHAS with:

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

2nd Resistance Point 3.43
1st Resistance Point 3.38
Last Price 3.32
1st Support Level 3.22
2nd Support Level 3.11

See More

52-Week High 16.65
Fibonacci 61.8% 11.27
Fibonacci 50% 9.60
Fibonacci 38.2% 7.94
Last Price 3.32
52-Week Low 2.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar